Journal of Medical Internet Research | Continuous Glucose Monitoring Type 2 Diabetes Control

Journal of Medical Internet Research | Continuous Glucose Monitoring Type 2 Diabetes Control

Source: Shutterstock;  Copyright: Lightfield Studios;  License: Licensed by JMIR

Source: Shutterstock; Copyright: Lightfield Studios; License: Licensed by JMIR

“Continuous Glucose Monitoring with Low-Carbohydrate Nutritional Coaching to Improve Type 2 Diabetes Control: Randomized Quality Improvement Program”

“Type 2 diabetes mellitus (T2DM) is a leading cause of morbidity and mortality worldwide, with adverse health consequences largely related to hyperglycemia.” “

– Dr Dina H Griauzde

TORONTO, CANADA, Dec. 13, 2022 /EINPresswire.com/ — JMIR Publications published “Continuous Glucose Monitoring with Low-Carbohydrate Dietary Coaching to Improve Type 2 Diabetes Control: Randomized Quality Improvement Program” in the Journal of Medical Internet Research, which aims to identify changes in To compare HbA1c levels between patients with suboptimally controlled type 2 diabetes mellitus (T2DM) who were given the opportunity to use an intermittent continuous glucose monitor (CGM) and receive personalized low-carbohydrate nutrition counseling versus those who received usual care. .

Included participants (“individuals with HbA1c> 7.5%…who were medically eligible for tighter glycemic control”) were divided into 2 groups: usual care-high risk (UC-HR) and enhanced care (EC)-HR. The primary outcome was the mean change in HbA1c levels from baseline to 12 months using an intention-to-treat difference-in-differences analysis comparing the EC-HR group with the UC-HR compared group. The authors also conducted follow-up semi-structured interviews to understand the EC-HR participants’ experiences with the intervention.

HbA1c decreased by 0.41% more for participants in the EC-HR group than those in the UC-HR from baseline to 12 months; however, only 61 of the 185 EC-HR participants engaged in the program. Among the EC-HR participants wearing CGMs, HbA1c was 1.1% lower at 12 months compared to baseline.

Dr. Dina H Griauzde, MSc, MD, of the VA Ann Arbor Healthcare System and the University of Michigan said: “type 2 diabetes mellitus (T2DM) is a leading cause of morbidity and mortality worldwide, with adverse health consequences largely related to with hyperglycemia.”

Unfortunately, despite recommendations for clinical practice guidelines, effective pharmacotherapy, and interventions to support patients and providers, it is estimated that up to 60% of patients with diagnosed T2DM have HbA1c levels above the recommended targets. Multifaceted barriers impede optimal glycemic control, including those at the patient, provider, and health system levels. Such barriers may be exacerbated by the high cost of many T2DM medications, including insulin.

New strategies that can be sustained and scaled up in diverse clinical settings are needed to help more patients with T2DM achieve the dual goals of glycemic control and reduced medication burden.

Dr. In their JMIR Publications Research Output, Griauzde and the research team concluded that “…the use of CGM technology and personalized nutritional counseling focused on dietary carbohydrate restriction can help patients with suboptimally controlled T2DM to improve HbA1c levels without increase the use of antihyperglycemic medications As CGM technology develops and carbohydrate restriction is increasingly accepted as a powerful tool to support T2DM self-management, this program may be a scalable and sustainable strategy to help and empower patients with T2DM to achieve glycemic control.

###

DOI – https://doi.org/10.2196/31184
Full text – https://www.jmir.org/2022/2/e31184/
Free Altmetric Report – https://jmir.altmetric.com/details/120002852

JMIR Publications is a leading, born-digital, open-access publisher of more than 30 academic journals and other innovative scholarly communication products that focus on the intersection of health and technology. Its flagship journal, the Journal of Medical Internet Research, is the leading digital health journal worldwide in content breadth and visibility, and it is the largest journal in the field of medical informatics.

To learn more about JMIR Publications, please visit https://www.JMIRPublications.com or contact us via:

YouTube – https://www.youtube.com/c/JMIRPublications
Facebook – https://www.facebook.com/JMedInternetRes
Twitter – https://twitter.com/jmirpub
LinkedIn – https://www.linkedin.com/company/jmir-publications
Instagram – https://www.instagram.com/jmirpub/

Head Office – 130 Queens Quay East, Unit 1100 Toronto, ON, M5A 0P6 Canada

Media Contact – [email protected]

The content of this communication is licensed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work, published by JMIR Publications, is duly cited.

JMIR Publications is a registered trademark of JMIR Publications.

Ryan James Jessup JD/MPA
JMIR Publications
+1 202-638-9720
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

Leave a Reply

Your email address will not be published. Required fields are marked *